This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Genne, P. Articles by Chauffert, B. Search for Related Content PubMed PubMed Citation Articles by Genne, P. Articles by Chauffert, B.

Cinchonine, a Potent Efflux Inhibitor to Circumvent Anthracycline Resistance In Vivo¹

Research Group on Digestive Tumors, INSERM U.252, Faculty of Medecine, University of Dijon, 21033 Dijon, France [P. G., M. T. B., J-M. P., F. M., B. C.]; Debiopharm, 1006 Lausanne, Switzerland [R. Y. M.]; and Texinfine, 69006 Lyon, France [P. G., G. G., O. D.]

Circumvention of multidrug resistance is a new field of investigation in cancer chemotherapy, and safe and potent multidrug resistance inhibitors are needed for clinical use. We investigated several analogues of quinine for their ability to increase anthracycline uptake in resistant cancer cells. Cinchonine was the most potent inhibitor of anthracycline resistance in vitro, and its activity was little altered by serum proteins. Serum from rats treated with i.v. cinchonine produced greater uptake of doxorubicin in cancer cells (DHD/K12/PROb rat colon cells and K562/ADM human leukemic cells) than did serum from quinine-treated rats (ex vivo assay). Cinchonine was more effective than quinine in reducing tumor mass and increasing the survival of rats inoculated i.p. with DHD/K12/PROb cells and treated i.p. with deoxydoxorubicin. Moreover, the acute toxicity of cinchonine in rats and mice was lower than that of other quinine-related compounds. The lower toxicity and greater potentiation of in vivo anthracycline activity produced by cinchonine are favorable characteristics for its use as an anti-multidrug resistance agent in future clinical trials.

¹ This work was supported by a grant from the Ligue Bourguignone Contre le Cancer (Dijon, France) and a grant from Région Rhône-Alpes.

² To whom requests for reprints should be addressed, at INSERM U.252, Faculty of Medecine, University of Dijon, 7 Bd Jeanne d'Arc, 21033 Dijon, France.

Received 7/15/91. Accepted 3/11/92.